Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives

SIMPLE SUMMARY: Around 5–10% of advanced melanoma patients progress early on anti-BRAF targeted therapy and 20–30% respond only with the stabilization of the disease. Presumably, these patients could benefit more from first-line immunotherapy. Resistance to BRAF/MEK inhibitors is generated by geneti...

Descripción completa

Detalles Bibliográficos
Autor principal: Olbryt, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102921/
https://www.ncbi.nlm.nih.gov/pubmed/35565444
http://dx.doi.org/10.3390/cancers14092315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102921/
https://www.ncbi.nlm.nih.gov/pubmed/35565444
http://dx.doi.org/10.3390/cancers14092315

Ejemplares similares